|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bruix J and Sherman M; American
Association for the Study of Liver Diseases, : Management of
hepatocellular carcinoma: An update. Hepatology. 53:1020–1022.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Tabrizian P, Jibara G, Shrager B, Schwartz
M and Roayaie S: Recurrence of hepatocellular cancer after
resection: Patterns, treatments, and prognosis. Ann Surg.
261:947–955. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Forner A, Reig M and Bruix J:
Hepatocellular carcinoma. Lancet. 391:1301–1314. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Omata M, Cheng AL, Kokudo N, Kudo M, Lee
JM, Jia J, Tateishi R, Han KH, Chawla YK, Shiina S, et al:
Asia-pacific clinical practice guidelines on the management of
hepatocellular carcinoma: A 2017 update. Hepatol Int. 11:317–370.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chan SL, Mo FK, Johnson PJ, Liem GS, Chan
TC, Poon MC, Ma BB, Leung TW, Lai PB, Chan AT, et al: Prospective
validation of the Chinese University prognostic index and
comparison with other staging systems for hepatocellular carcinoma
in an Asian population. J Gastroenterol Hepatol. 26:340–347. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Yang B, Zheng B, Yang M, Zeng Z, Yang F,
Pu J, Li C and Liao Z: Liver resection versus transarterial
chemoembolization for the initial treatment of Barcelona clinic
liver cancer stage B hepatocellular carcinoma. Hepatol Int.
12:417–428. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Marquardt JU, Galle PR and Teufel A:
Molecular diagnosis and therapy of hepatocellular carcinoma (HCC):
An emerging field for advanced technologies. J Hepatol. 56:267–275.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chance MR, Chang J, Liu S, Gokulrangan G,
Chen DH, Lindsay A, Geng R, Zheng QY and Alagramam K: Proteomics,
bioinformatics and targeted gene expression analysis reveals
up-regulation of cochlin and identifies other potential biomarkers
in the mouse model for deafness in Usher syndrome type 1F. Hum Mol
Genet. 19:1515–1527. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ikezono T, Matsumura T, Matsuda H, Shikaze
S, Saitoh S, Shindo S, Hasegawa S, Oh SH, Hagiwara Y, Ogawa Y, et
al: The diagnostic performance of a novel ELISA for human CTP
(Cochlin-tomoprotein) to detect perilymph leakage. PLoS One.
13:e01914982018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jung J, Kim HS, Lee MG, Yang EJ and Choi
JY: Novel COCH p.V123E mutation, causative of DFNA9 sensorineural
hearing loss and vestibular disorder, shows impaired cochlin
post-translational cleavage and secretion. Hum Mutat. 36:1168–1175.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nyström A, Bornert O, Kühl T, Gretzmeier
C, Thriene K, Dengjel J, Pfister-Wartha A, Kiritsi D and
Bruckner-Tuderman L: Impaired lymphoid extracellular matrix impedes
antibacterial immunity in epidermolysis bullosa. Proc Natl Acad Sci
USA. 115:E705–E714. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Oken MM, Creech RH, Tormey DC, Horton J,
Davis TE, McFadden ET and Carbone PP: Toxicity and response
criteria of the Eastern cooperative oncology group. Am J Clin
Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Suman A, Barnes DS, Zein NN, Levinthal GN,
Connor JT and Carey WD: Predicting outcome after cardiac surgery in
patients with cirrhosis: A comparison of Child-Pugh and MELD
scores. Clin Gastroenterol Hepatol. 2:719–723. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang K, Liu J, Yan ZL, Li J, Shi LH, Cong
WM, Xia Y, Zou QF, Xi T, Shen F, et al: Overexpression of
aspartyl-(asparaginyl)- beta-hydroxylase in hepatocellular
carcinoma is associated with worse surgical outcome. Hepatology.
52:164–173. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Dong LW, Hou YJ, Tan YX, Tang L, Pan YF,
Wang M and Wang HY: Prognostic significance of Beclin 1 in
intrahepatic cholangiocellular carcinoma. Autophagy. 7:1222–1229.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang Q, Tan YX, Ren YB, Dong LW, Xie ZF,
Tang L, Cao D, Zhang WP, Hu HP and Wang HY: Zinc finger protein
ZBTB20 expression is increased in hepatocellular carcinoma and
associated with poor prognosis. BMC Cancer. 11:2712011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Bas A, Forsberg G, Hammarström S and
Hammarström ML: Utility of the housekeeping genes 18S rRNA,
beta-actin and glyceraldehyde-3-phosphate-dehydrogenase for
normalization in real-time quantitative reverse
transcriptase-polymerase chain reaction analysis of gene expression
in human T lymphocytes. Scand J Immunol. 59:566–573. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Marrero JA, Kulik LM, Sirlin CB, Zhu AX,
Finn RS, Abecassis MM, Roberts LR and Heimbach JK: Diagnosis,
staging, and management of hepatocellular carcinoma: 2018 Practice
guidance by the american association for the study of liver
diseases. Hepatology. 68:723–750. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kim JM, Lee SH, Shin WY, Lee KY, Kim JM
and Ahn SI: Intrahepatic recurrence of single nodular
hepatocellular carcinoma after surgical resection: An analysis by
segmental distribution. ANZ J Surg. 88:E840–E844. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang K, Liu G, Li J, Yan Z, Xia Y, Wan X,
Ji Y, Lau WY, Wu M and Shen F: Early intrahepatic recurrence of
hepatocellular carcinoma after hepatectomy treated with
re-hepatectomy, ablation or chemoembolization: A prospective cohort
study. Eur J Surg Oncol. 41:236–242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Huang L, Li J, Yan J, Cao J, Liu C, Zhang
X, Wu M and Yan Y: Early recurrence after curative resection in
oligonodular hepatocellular carcinoma. Hepatogastroenterology.
60:28–31. 2013.PubMed/NCBI
|
|
24
|
Feng AL, Zhu JK, Yang Y, Wang YD, Liu FY,
Zhu M and Liu CZ: Repeated postoperative adjuvant TACE after
curative hepatectomy improves outcomes of patients with HCC. Minim
Invasive Ther Allied Technol. 1–6. Dec 27–2019.(Epub ahead of
print). doi: 10.1080/13645706.2019.1707689. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen J, Huang J, Chen M, Yang K, Chen J,
Wang J, Xu L, Zhou Z and Zhang Y: Transcatheter arterial
chemoembolization (TACE) versus hepatectomy in hepatocellular
carcinoma with macrovascular invasion: A meta-analysis of 1683
patients. J Cancer. 8:2984–2991. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Llovet JM and Bruix J: Systematic review
of randomized trials for unresectable hepatocellular carcinoma:
Chemoembolization improves survival. Hepatology. 37:429–442. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lencioni R, de Baere T, Soulen MC, Rilling
WS and Geschwind JF: Lipiodol transarterial chemoembolization for
hepatocellular carcinoma: A systematic review of efficacy and
safety data. Hepatology. 64:106–116. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Oliveri RS, Wetterslev J and Gluud C:
Transarterial (chemo)embolisation for unresectable hepatocellular
carcinoma. Cochrane Database Syst Rev. CD0047872011.PubMed/NCBI
|
|
29
|
Forner A, Llovet JM and Bruix J:
Chemoembolization for intermediate HCC: Is there proof of survival
benefit? J Hepatol. 56:984–986. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Farinati F, Giacomin A, Vanin V, Giannini
E and Trevisani F: TACE treatment in hepatocellular carcinoma: What
should we do now? J Hepatol. 57:221–222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li KW, Li X, Wen TF and Lu WS: The effect
of postoperative TACE on prognosis of HCC: An update.
Hepatogastroenterology. 60:248–251. 2013.PubMed/NCBI
|
|
32
|
Zhang Y, Chen SW, Liu LL, Yang X, Cai SH
and Yun JP: A model combining TNM stage and tumor size shows
utility in predicting recurrence among patients with hepatocellular
carcinoma after resection. Cancer Manag Res. 10:3707–3715. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Li L, Ikezono T, Watanabe A, Shindo S,
Pawankar R and Yagi T: Expression of full-length Cochlin p63s is
inner ear specific. Auris Nasus Larynx. 32:219–223. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Galle PR, Tovoli F, Foerster F, Wörns MA,
Cucchetti A and Bolondi L: The treatment of intermediate stage
tumours beyond TACE: From surgery to systemic therapy. J Hepatol.
67:173–183. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Miksad RA, Ogasawara S, Xia F, Fellous M
and Piscaglia F: Liver function changes after transarterial
chemoembolization in US hepatocellular carcinoma patients: The
LiverT study. BMC Cancer. 19:7952019. View Article : Google Scholar : PubMed/NCBI
|
